lvgn7409
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04635995)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06159621 | Phase 1 | Mar 1, 2024 | University of Pennsylvania |
| NCT05075993 | Phase 1 | Nov 12, 2021 | Lyvgen Biopharma Holdings Limited, University of Texas at Houston |
| NCT05152212 | Phase 1 | Oct 18, 2021 | Lyvgen Biopharma Holdings Limited |
| NCT04635995 | Phase 1 | Dec 31, 2020 | Lyvgen Biopharma Holdings Limited |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lyvgen Biopharma Holdings Limited | For profit | 3 | 2 | 1 | 2020 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1